About: Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases
Creator	Nuñez, Freites
Source	Medline; PMC
abstract	OBJECTIVES: To describe patients with autoimmune inflammatory rheumatic diseases (AIRD) who had COVID-19 disease; to compare patients who required hospital admission with those who did not and assess risk factors for hospital admission related to COVID-19. METHODS: An observational longitudinal study was conducted during the pandemic peak of severe acute respiratory syndrome coronavirus 2 (1 March 2020 to 24 April). All patients attended at the rheumatology outpatient clinic of a tertiary hospital in Madrid, Spain with a medical diagnosis of AIRD and with symptomatic COVID-19 were included. The main outcome was hospital admission related to COVID-19. The covariates were sociodemographic, clinical and treatments. We ran a multivariable logistic regression model to assess risk factors for the hospital admission. RESULTS: The study population included 123 patients with AIRD and COVID-19. Of these, 54 patients required hospital admission related to COVID-19. The mean age on admission was 69.7 (15.7) years, and the median time from onset of symptoms to hospital admission was 5 (3–10) days. The median length of stay was 9 (6–14) days. A total of 12 patients died (22%) during admission. Compared with outpatients, the factors independently associated with hospital admission were older age (OR: 1.08; p=0.00) and autoimmune systemic condition (vs chronic inflammatory arthritis) (OR: 3.55; p=0.01). No statistically significant findings for exposure to disease-modifying antirheumatic drugs were found in the final model. CONCLUSION: Our results suggest that age and having a systemic autoimmune condition increased the risk of hospital admission, whereas disease-modifying antirheumatic drugs were not associated with hospital admission.
has issue date	2020-08-07(xsd:dateTime)
bibo:doi	10.1136/annrheumdis-2020-217984
bibo:pmid	32769150
has license	no-cc
sha1sum (hex)	e0e3b89a8f8b17036724aade41c4a91f0301c028
schema:url	https://doi.org/10.1136/annrheumdis-2020-217984
resource representing a document's title	Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases
has PubMed Central identifier	PMC7415073
has PubMed identifier	32769150
schema:publication	Ann Rheum Dis
resource representing a document's body	covid:e0e3b89a8f8b17036724aade41c4a91f0301c028#body_text
is schema:about of	named entity 'patients' named entity 'rheumatic diseases' named entity 'hospital admissions' named entity 'inflammatory' named entity 'clinical history' named entity 'rituximab' named entity 'comorbidities' named entity 'outpatient clinic' named entity 'methotrexate' named entity 'hypertension' named entity 'COVID-19' named entity 'hospital admission' named entity 'risk factors' named entity 'median age' named entity 'tertiary hospital' named entity 'rheumatic disease' named entity 'glucocorticoids' named entity 'medical diagnosis' named entity 'comorbidities' named entity 'Spain' named entity 'hypertension' named entity 'infusion' named entity 'autoimmune' named entity 'risk factors' named entity 'diabetes' named entity 'psoriatic arthritis' named entity 'acute-phase reactants' named entity 'adalimumab' named entity 'Spain' named entity 'COVID-19' named entity 'logistic regression' named entity 'COVID' named entity 'antibody' named entity 'lung disease' named entity 'rheumatic diseases' named entity 'rheumatic disease' named entity 'glucocorticoids' named entity 'Epidemiology' named entity 'median age' named entity 'hospital admissions' named entity 'tocilizumab' named entity 'COVID-19' named entity 'D-dimers' named entity 'hospital admission' named entity 'IL-6' named entity 'self-isolation' named entity 'rheumatic disease' named entity 'vasculitis' named entity 'mycophenolic acid' named entity '5.7' named entity 'IL-6' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'stroke' named entity 'PCR' named entity 'D-dimer' named entity 'inflammatory arthritis' named entity 'rheumatology' named entity 'diagnostic test' named entity 'tumour necrosis factor-alpha' named entity 'lung disease' named entity 'autoimmune conditions' named entity 'pulmonary disease' named entity 'confounders' named entity 'antimalarials' named entity 'hospital admission' named entity 'thrombosis' named entity 'ICD-10' named entity 'comorbidity' named entity 'glucocorticoids' named entity 'statistically significant' named entity 'COVID' named entity 'morbidity' named entity 'Stata' named entity 'chronic obstructive pulmonary disease' named entity 'kidney disease' named entity 'interleukin (IL)-6' named entity '95% CI' named entity 'diabetes mellitus' named entity 'Autonomous Community of Madrid' named entity 'observational study'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software